Skip to Main Content
Contribute Try STAT+ Today

In its latest bid to defend its franchise product, AbbVie (ABBV) has filed a complaint with the U.S. International Trade Commission in hopes of preventing a would-be rival from selling a lower-cost version of its Humira treatment for rheumatoid arthritis and other ailments.

The drug maker argued that Alvotech, which is seeking a toehold in the U.S. for biosimilar medicines, misappropriated trade secrets and should not be allowed to market its version once it becomes available in the U.S. Alvotech, which is based in Iceland, is awaiting regulatory approval after the U.S. Food and Drug Administration cited pandemic travel restrictions that delayed plant inspections.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment